Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...

is also one of the first antibodies recruited by the immune system to fight infection. IgM populations rise very quickly when the body is first confronted with an infectious organism, and then they ...

There are several types of antibodies, and IgG antibodies are associated with chronic (long-term) disease or long-term response to an infection. Normally, the body has minimal or undetectable levels ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK — Werfen said Monday that it has received US Food and Drug Administration 510(k) clearance for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) ...

IGM Biosciences Background Information (This ... their inherent properties may provide advantages as compared to IgG antibodies. Fintel is one of the most comprehensive investing research ...

The company now lists a lone, Sanofi-partnered IgM antibody asset on its pipeline. The treatment, which the partners hope to pit against immunology and inflammation targets, is still in the ...

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...

MIT’s new AI model predicts antibody structures with greater accuracy, aiding disease treatment and streamlining drug discovery. With this model, researchers may be able to discover antibody drugs ...

and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com. Cautionary Note Regarding Forward-Looking Statements This ...